MCMargaret Cote

Margaret Cote

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret Cote has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Vikash S. Oza

    The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA

    4 shared publications
  • Archie Spindler

    The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA

    3 shared publications
  • Derek Maas

    The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA

    3 shared publications
  • Amber Dahlin

    Department of Medicine, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA

    2 shared publications
  • Ann Chen Wu

    Harvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, USA

    2 shared publications
  • Carli Needle Lawrence

    The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York New York USA

    2 shared publications

Latest Publications

  • Fibrosing Alopecia in a Pattern Distribution in the Pediatric Population: A Potentially Underdiagnosed Entity

    by Margaret Cote, Carli Needle Lawrence, Kristen I. Lo Sicco, Nicole Weiler, Vikash S. Oza, Michael Occidental, Seth J. Orlow

    Fibrosing alopecia in a pattern distribution (FAPD) is an uncommon scarring alopecia with features of androgenetic alopecia (AGA) and lichen planopilaris (LPP); pediatric disease is poorly characterized. We report three male patients aged 12–16 years with patterned hair loss, dermoscopic miniaturization/follicular dropout, and histopathology showing perifollicular lymphocytic inflammation and fibrosis, fulfilling FAPD criteria. This case series highlights the need for early histopathologic confirmation to enable timely treatment and prevent irreversible scarring in pediatric FAPD.

  • Open Access

    Cutaneous Clues to Lymphatic Disease: Bedside Recognition of Lymphedema, Lymphatic Malformations, and Mimics

    by Ronan Talty, Margaret Cote, Vikash S. Oza

    Lymphatic disorders encompass a diverse group of congenital and acquired conditions that often first manifest in the skin. Edema, vesicles, verrucous change, erythema, and vascular-appearing lesions overlap with common venous, infectious, neoplastic, and systemic disorders, which makes recognition of lymphatic disease challenging and contributes to diagnostic delay. This review examines the cutaneous manifestations of lymphedema and lymphatic malformations with an emphasis on bedside diagnosis, common mimics, and clinically important pitfalls. We first discuss the clinical evolution of lymphedema and features that distinguish primary from secondary disease, including infectious and oncologic causes and complications. We then review superficial and deep lymphatic malformations, acquired lymphangiectasia, and syndromic disorders including PIK3CA-related overgrowth spectrum and complex lymphatic anomalies. Throughout, we highlight practical clues that can guide imaging, biopsy, genetic evaluation, and multidisciplinary referral.

  • Bridging Therapy and Safety of Low‐Dose Oral Minoxidil: A Novel Investigation of a Common Approach

    by Derek Maas, Archie Spindler, Isabella Zappi, Jolie Kantor, Margaret Cote, Sarah Go, Esha Patel, Jerry Shapiro, Kristen I. Lo Sicco

  • Circadian rhythm and minoxidil: avenues for further investigation

    by Derek Maas, Archie Spindler, Isabella Zappi, Margaret Cote, Jolie Kantor, Esha Patel, Sarah Go, Ian M Ahearn, Ian W Tattersall, Lynn Petukhova, et al.

    This letter to the editor is the authors’ reply to ‘Daytime oral minoxidil: a new question and an open mechanism’ by Sareen and Donovan.

  • Depictions of Alopecia in Children's Animated Films: A Cross‐Studio Analysis

    by Carli Needle Lawrence, Derek E. Maas, Archie J. Spindler, Isabella Zappi, Margaret Cote, Anna L. Brinks, Caitlin A. Kearney, Carli Tucci, Annalie M. Brody, Ambika Nohria, et al.

    Children with alopecia experience significant psychosocial challenges, and portrayals in animated films may shape how young audiences perceive hair loss and identity. Alopecia representation across 139 children's animated films from Disney, Pixar, DreamWorks, and Studio Ghibli was analyzed, identifying 177 total characters that were verified by a hair specialist dermatologist and evaluated by independent raters, with statistical comparisons performed using χ 2 and Fisher's exact tests. Characters with alopecia were predominantly male, human, and peripheral, with androgenetic alopecia most common; overall, they were more frequently depicted as intelligent, leaders, and heroes, although female characters were more often portrayed as villainous or frightening, and children as clumsy. Despite some positive associations, these findings highlight persistent sex‐ and age‐based disparities, suggesting a cultural bias that frames male‐pattern hair loss favorably while reinforcing stigmatizing portrayals in women and children, underscoring the need for more balanced and inclusive representation.

  • Are Pediatric GLP ‐1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age‐Specific Patterns and Their Implications for Dermatologists

    by Margaret F. Cote, Vikash S. Oza, Seth J. Orlow

    Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) use in children is rapidly expanding, though in contrast to adults, morphologic data on dermatologic adverse events (AEs) in pediatric patients remain sparse, underscoring the need for further focused investigation. We review and synthesize the existing literature on dermatologic AEs of GLP‐1 RAs in children in comparison to adults, to summarize current evidence, identify knowledge gaps, and highlight areas for future research. Available reports suggest that rash, urticaria, and alopecia may occur with greater frequency in children on injectable GLP‐1 RAs compared with adults, while facial lipodystrophy has been more often described in adults. However, pediatric dermatologic AE data are not as robust as adult data, reducing the ability for direct comparisons. Based on this initial investigation, dermatologic AEs of GLP‐1 RAs are seemingly under‐described in children and may have important differences compared with adult dermatologic AEs.


  • PHACE (S) Syndrome Minus the H: A Case of Possible PHACE (S) Syndrome Without an Infantile Hemangioma

    by Margaret F. Cote, Evan G. Stein, Vikash S. Oza

    A 4‐month‐old, full‐term girl was referred for evaluation of a supraumbilical raphe and an anomalous aortic arch. Further work up for PHACE(S) syndrome was pursued, despite the absence of a cutaneous infantile hemangioma (IH), which identified hypoplastic and dysplastic cerebral vasculature. We present this case to raise awareness of possible PHACE(S) syndrome even in children without cutaneous IHs and the importance of recognizing supraumbilical raphe as a sentinel finding.

  • Author Correction: Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma

    by Priyadarshini Kachroo, Isobel D. Stewart, Rachel S. Kelly, Meryl Stav, Kevin Mendez, Amber Dahlin, Djøra I. Soeteman, Su H. Chu, Mengna Huang, Margaret Cote, et al.


  • Top Cited Papers

    Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma

    by Priyadarshini Kachroo, Isobel D. Stewart, Rachel S. Kelly, Meryl Stav, Kevin Mendez, Amber Dahlin, Djøra I. Soeteman, Su H. Chu, Mengna Huang, Margaret Cote, et al.

    The application of large-scale metabolomic profiling provides new opportunities for realizing the potential of omics-based precision medicine for asthma. By leveraging data from over 14,000 individuals in four distinct cohorts, this study identifies and independently replicates 17 steroid metabolites whose levels were significantly reduced in individuals with prevalent asthma. Although steroid levels were reduced among all asthma cases regardless of medication use, the largest reductions were associated with inhaled corticosteroid (ICS) treatment, as confirmed in a 4-year low-dose ICS clinical trial. Effects of ICS treatment on steroid levels were dose dependent; however, significant reductions also occurred with low-dose ICS treatment. Using information from electronic medical records, we found that cortisol levels were substantially reduced throughout the entire 24-hour daily period in patients with asthma who were treated with ICS compared to those who were untreated and to patients without asthma. Moreover, patients with asthma who were treated with ICS showed significant increases in fatigue and anemia as compared to those without ICS treatment. Adrenal suppression in patients with asthma treated with ICS might, therefore, represent a larger public health problem than previously recognized. Regular cortisol monitoring of patients with asthma treated with ICS is needed to provide the optimal balance between minimizing adverse effects of adrenal suppression while capitalizing on the established benefits of ICS treatment.